Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
Identifieur interne : 000636 ( Main/Exploration ); précédent : 000635; suivant : 000637Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
Auteurs : Hélène Pasquini-Descomps [Suisse] ; Nathalie Brender [Suisse] ; David Maradan [Suisse]Source :
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [ 1524-4733 ] ; 2017.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Antiviraux (administration et posologie), Antiviraux (ressources et distribution), Antiviraux (économie), Grippe humaine (), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Pandémies (), Pandémies (économie), Sous-type H1N1 du virus de la grippe A, Vaccination (économie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (économie), Évaluation des risques ().
- MESH :
- administration et posologie : Antiviraux, Vaccins antigrippaux.
- ressources et distribution : Antiviraux.
- économie : Antiviraux, Grippe humaine, Pandémies, Vaccination, Vaccins antigrippaux.
- épidémiologie : Grippe humaine.
- Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Grippe humaine, Humains, Pandémies, Sous-type H1N1 du virus de la grippe A, Évaluation des risques.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (economics), Antiviral Agents (supply & distribution), Cost-Benefit Analysis, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Pandemics (economics), Pandemics (prevention & control), Quality-Adjusted Life Years, Risk Assessment (methods), Vaccination (economics).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Influenza Vaccines.
- chemical , economics : Antiviral Agents, Influenza Vaccines.
- chemical , supply & distribution : Antiviral Agents.
- economics : Influenza, Human, Pandemics, Vaccination.
- epidemiology : Influenza, Human.
- methods : Risk Assessment.
- prevention & control : Influenza, Human, Pandemics.
- Cost-Benefit Analysis, Humans, Influenza A Virus, H1N1 Subtype, Quality-Adjusted Life Years.
Abstract
The 2009 A/H1N1 influenza pandemic generated additional data and triggered new studies that opened debate over the optimal strategy for handling a pandemic. The lessons-learned documents from the World Health Organization show the need for a cost estimation of the pandemic response during the risk-assessment phase. Several years after the crisis, what conclusions can we draw from this field of research?
DOI: 10.1016/j.jval.2016.05.005
PubMed: 28577700
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000408
- to stream PubMed, to step Curation: 000408
- to stream PubMed, to step Checkpoint: 000343
- to stream Ncbi, to step Merge: 001C79
- to stream Ncbi, to step Curation: 001C79
- to stream Ncbi, to step Checkpoint: 001C79
- to stream Main, to step Merge: 000638
- to stream Main, to step Curation: 000636
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.</title><author><name sortKey="Pasquini Descomps, Helene" sort="Pasquini Descomps, Helene" uniqKey="Pasquini Descomps H" first="Hélène" last="Pasquini-Descomps">Hélène Pasquini-Descomps</name><affiliation wicri:level="4"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva, Switzerland. Electronic address: helene.pasquini-descomps@hesge.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva</wicri:regionArea><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName><orgName type="university">Université de Genève</orgName></affiliation></author><author><name sortKey="Brender, Nathalie" sort="Brender, Nathalie" uniqKey="Brender N" first="Nathalie" last="Brender">Nathalie Brender</name><affiliation wicri:level="1"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge</wicri:regionArea><wicri:noRegion>Carouge</wicri:noRegion></affiliation></author><author><name sortKey="Maradan, David" sort="Maradan, David" uniqKey="Maradan D" first="David" last="Maradan">David Maradan</name><affiliation wicri:level="4"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva</wicri:regionArea><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName><orgName type="university">Université de Genève</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28577700</idno><idno type="pmid">28577700</idno><idno type="doi">10.1016/j.jval.2016.05.005</idno><idno type="wicri:Area/PubMed/Corpus">000408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000408</idno><idno type="wicri:Area/PubMed/Curation">000408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000408</idno><idno type="wicri:Area/PubMed/Checkpoint">000343</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000343</idno><idno type="wicri:Area/Ncbi/Merge">001C79</idno><idno type="wicri:Area/Ncbi/Curation">001C79</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C79</idno><idno type="wicri:Area/Main/Merge">000638</idno><idno type="wicri:Area/Main/Curation">000636</idno><idno type="wicri:Area/Main/Exploration">000636</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.</title><author><name sortKey="Pasquini Descomps, Helene" sort="Pasquini Descomps, Helene" uniqKey="Pasquini Descomps H" first="Hélène" last="Pasquini-Descomps">Hélène Pasquini-Descomps</name><affiliation wicri:level="4"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva, Switzerland. Electronic address: helene.pasquini-descomps@hesge.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva</wicri:regionArea><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName><orgName type="university">Université de Genève</orgName></affiliation></author><author><name sortKey="Brender, Nathalie" sort="Brender, Nathalie" uniqKey="Brender N" first="Nathalie" last="Brender">Nathalie Brender</name><affiliation wicri:level="1"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge</wicri:regionArea><wicri:noRegion>Carouge</wicri:noRegion></affiliation></author><author><name sortKey="Maradan, David" sort="Maradan, David" uniqKey="Maradan D" first="David" last="Maradan">David Maradan</name><affiliation wicri:level="4"><nlm:affiliation>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Haute École de Gestion Genève (Geneva School of Business Administration), HES-SO University of Applied Sciences Western Switzerland, Carouge, Switzerland; University of Geneva</wicri:regionArea><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName><orgName type="university">Université de Genève</orgName></affiliation></author></analytic><series><title level="j">Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</title><idno type="eISSN">1524-4733</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (economics)</term><term>Antiviral Agents (supply & distribution)</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Pandemics (economics)</term><term>Pandemics (prevention & control)</term><term>Quality-Adjusted Life Years</term><term>Risk Assessment (methods)</term><term>Vaccination (economics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (ressources et distribution)</term><term>Antiviraux (économie)</term><term>Grippe humaine ()</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Pandémies ()</term><term>Pandémies (économie)</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (économie)</term><term>Évaluation des risques ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiviral Agents</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Risk Assessment</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antiviraux</term><term>Grippe humaine</term><term>Pandémies</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Quality-Adjusted Life Years</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Grippe humaine</term><term>Humains</term><term>Pandémies</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2009 A/H1N1 influenza pandemic generated additional data and triggered new studies that opened debate over the optimal strategy for handling a pandemic. The lessons-learned documents from the World Health Organization show the need for a cost estimation of the pandemic response during the risk-assessment phase. Several years after the crisis, what conclusions can we draw from this field of research?</div></front></TEI><affiliations><list><country><li>Suisse</li></country><region><li>Canton de Genève</li></region><settlement><li>Genève</li></settlement><orgName><li>Université de Genève</li></orgName></list><tree><country name="Suisse"><region name="Canton de Genève"><name sortKey="Pasquini Descomps, Helene" sort="Pasquini Descomps, Helene" uniqKey="Pasquini Descomps H" first="Hélène" last="Pasquini-Descomps">Hélène Pasquini-Descomps</name></region><name sortKey="Brender, Nathalie" sort="Brender, Nathalie" uniqKey="Brender N" first="Nathalie" last="Brender">Nathalie Brender</name><name sortKey="Maradan, David" sort="Maradan, David" uniqKey="Maradan D" first="David" last="Maradan">David Maradan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000636 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000636 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28577700
|texte= Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28577700" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |